烟雾病市场
烟雾病市场：2026年市场规模约为13.8亿美元，2031年市场规模约为18亿美元；预测期复合年增长率为5.45%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
烟雾病市场：2026年市场规模约为13.8亿美元，2031年市场规模约为18亿美元；预测期复合年增长率为5.45%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 5.45% | 机构预测 |
| 市场规模 | 2026 | USD 1.38 billion | 机构预测 |
| 市场规模 | 2031 | USD 1.8 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| clinical_presentation | ischemic presentation | 2025 | 68.240% |
| end_user | hospitals | 2025 | 51.560% |
| geography | North America | 2025 | 38.610% |
| offering | treatment | 2025 | 68.310% |
| patient_demographic | adult patients | 2025 | 55.440% |
关键结论
- clinical_presentation 维度中，ischemic presentation 在 2025 年的公开份额为 68.24%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 51.56%。
- geography 维度中，North America 在 2025 年的公开份额为 38.61%。
- offering 维度中，treatment 在 2025 年的公开份额为 68.31%。
- patient_demographic 维度中，adult patients 在 2025 年的公开份额为 55.44%。
主要参与者
- Medtronic plc
- Stryker Corporation
- Johnson & Johnson
- Terumo Corporation
- Siemens Healthineers AG
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Diagnosis Through Advanced Neurovascular Imaging | +1.200% | Global, highest in Japan, South Korea, China, and North America | Medium term (2-4 years) |
| Higher Recognition of Pediatric and Adult Stroke Phenotypes | +0.900% | Global, led by North America and Europe with accelerating uptake in Asia-Pacific | Short term (≤ 2 years) |
| Expansion of Specialist Revascularization Capacity | +1.000% | Asia-Pacific core, with spillover to North America and Europe | Medium term (2-4 years) |
| Increasing Rare-Disease Research and Reimbursement Support | +0.800% | North America and Europe, with emerging support in Japan under its designated rare-disease framework | Long term (≥ 4 years) |
| AI-Assisted MRA and Retinal Screening for Case Finding | +0.700% | Global, with early adoption in Japan and the United States | Short term (≤ 2 years) |
| Collateral-Promotion Therapies Creating an Adjunctive Treatment Category | +0.500% | Global, with clinical trial activity concentrated in Japan and China | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Limited High-Level Evidence and Heterogeneous Treatment Guidelines | -0.600% | Global, most acute in North America and Europe where payer authorization relies on randomized evidence | Long term (≥ 4 years) |
| High Surgical Complexity and Concentration of Expertise | -0.500% | Emerging markets, including the Middle East, Africa, and South America, and smaller European markets | Medium term (2-4 years) |
| Perioperative Ischemia, Hyperperfusion, and Hemorrhagic Risk | -0.400% | Global, highest in high-volume centers managing complex bilateral cases | Short term (≤ 2 years) |
| Delayed Collateral Formation and Uncertain Commercial Path for Disease-Modifying Therapies | -0.300% | Global, with clinical trial activity in Japan and China | Long term (≥ 4 years) |
报告关注的关键问题
What is the forecast growth rate for moyamoya disease diagnosis and treatment?
The category is projected to grow at a 5.45% CAGR from 2026 to 2031, reaching USD 1.80 billion by 2031.
Which offering is expected to grow the fastest?
Diagnosis is forecast to grow at a 6.38% CAGR through 2031, supported by wider MRA use and AI-supported image interpretation.
Why are specialized neurology and neurosurgery centers expanding?
Neurology and neurosurgery centers are forecast to grow at a 7.95% CAGR through 2031 because complex bypass care requires specialized teams, intraoperative tools, and perfusion monitoring.
Which region has the highest growth outlook for moyamoya disease care?
Asia-Pacific is forecast to grow at a 7.65% CAGR through 2031, supported by high disease prevalence and updated care pathways.
What limits adoption of revascularization procedures?
Limited randomized evidence, inconsistent payer criteria, and the concentration of trained bypass surgeons can delay or restrict access.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence